Patents by Inventor Jean-Christophe Leroux

Jean-Christophe Leroux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190183800
    Abstract: The present invention provides polymersomes comprising non-biodegradable amphiphilic block-copolymers and their enteral (e.g., oral) or topical use in the treatment of an ammonia or ammonia methylated analog-associated disease or disorder or symptom thereof (e.g., hyperammonemia or trimethylaminuria). More particularly, it provides a polymersome comprising (a) a membrane, which comprises a block copolymer of poly(styrene) (PS) and poly(ethylene oxide) (PEO), wherein the PS/PEO molecular weight ratio is higher than 1.0 and lower than 4.0; and (b) a core which encloses an acid. It also provides a method of making the polymersome comprising mixing the copolymer-containing organic solvent phase with an aqueous phase containing the acid.
    Type: Application
    Filed: August 15, 2017
    Publication date: June 20, 2019
    Applicant: ETH Zurich
    Inventors: Jean-Christophe Leroux, Simon Matoori, Aaron Christoph Schmidt
  • Publication number: 20190175627
    Abstract: The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.
    Type: Application
    Filed: December 12, 2016
    Publication date: June 13, 2019
    Applicants: ETH Zurich, UNIVERSITAT BERN
    Inventors: Mattias IVARSSON, Bastien CASTAGNER, Jean-Christophe LEROUX, Andreas PASCH
  • Publication number: 20190105270
    Abstract: The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the pH within the liposomes differs from the pH in the intraperitoneal cavity and wherein the pH within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes. A further aspect of the present invention relates to a method of treating patients suffering from endogenous or exogenous toxicopathies, preferably selected from drug, metabolite, pesticide, insecticide, toxin, and chemical warfare toxicopathies, more preferably hyperammonemia, comprising the step of administering liposomes of the invention in a therapeutically effective amount into the peritoneal space of a patient in need thereof. Next to human, the present invention is particularly suitable to veterinary aspects.
    Type: Application
    Filed: October 19, 2018
    Publication date: April 11, 2019
    Inventors: Jean-Christophe Leroux, Vincent Forster
  • Publication number: 20180362554
    Abstract: The present invention relates to inositol bisthiophosphates-tetrakissulfates, particularly for use in treating symptoms associated with Clostridium difficile infection.
    Type: Application
    Filed: December 12, 2016
    Publication date: December 20, 2018
    Applicant: ETH Zurich
    Inventors: Mattias IVARSSON, Jean-Christophe LEROUX, Bastien CASTAGNER
  • Publication number: 20180110882
    Abstract: This invention describes compositions comprising indocyanine green and poly(N-vinylpyrrolidone) and methods of making the same as well as applications thereof for diagnostic and therapeutic uses. One of those applications is the structural and functional assessment of the lymphatic system by fluorescence imaging.
    Type: Application
    Filed: May 10, 2016
    Publication date: April 26, 2018
    Inventors: Jean-Christophe LEROUX, Michael DETMAR, Davide BRAMBILLA, Steven PROULX
  • Publication number: 20180104189
    Abstract: The invention relates to a method for preparing transmembrane pH-gradient vesicles. This method includes the following steps: a) preparing vesicles made from at least one matrix substance in an aqueous medium having an osmolarity of not more than 200 mOsm/l. The matrix substance is chosen from the group consisting of amphiphilic lipids and amphiphilic block copolymers, b) transferring the vesicles into a basic or acidic buffer having an osmolarity being at least 200 mOsm/l higher than the osmolarity of the aqueous medium of step a) to apply an osmotic shock to the vesicles and to obtain buffer-filled vesicles and c) diluting a mixture of the aqueous medium and the basic or acidic buffer containing the buffer-filled vesicles by adding a neutralizing solution to obtain transmembrane pH-gradient vesicles suspended in a suspension buffer, which differs from the basic or acidic buffer in pH value.
    Type: Application
    Filed: May 3, 2016
    Publication date: April 19, 2018
    Inventors: Jean-Christophe Leroux, Vincent Forster, Valentina Agostoni
  • Patent number: 9763978
    Abstract: A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: September 19, 2017
    Assignee: Valorisation-Recherche, Limited Partnership
    Inventors: Jean-Christophe Leroux, Mohamad Nasser Eddine
  • Patent number: 9751903
    Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently from other X can be OPO32?, OPSO22? or OSO3?; R1 is a solubility function such as a polyethylene glycol moiety. The invention further relates to the use of the compounds according to the invention in the therapy of infection by Clostridium difficile.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: September 5, 2017
    Assignee: ETH ZURICH
    Inventors: Bastien Castagner, Jean-Christophe Leroux, Mattias Ivarsson, Gisbert Schneider, Anna Pratsinis
  • Publication number: 20160280727
    Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently from other X can be OPO32?, OPSO22? or OSO3?; R1 is a solubility function such as a polyethylene glycol moiety. The invention further relates to the use of the compounds according to the invention in the therapy of infection by Clostridium difficile.
    Type: Application
    Filed: June 3, 2016
    Publication date: September 29, 2016
    Applicant: ETH Zurich
    Inventors: Bastien CASTAGNER, Jean-Christophe LEROUX, Mattias IVARSSON, Gisbert SCHNEIDER, Anna PRATSINIS
  • Patent number: 9358243
    Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO32?, OPSO22? or OSO3?; R1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO32?, OPSO22?, ? or OSO3?; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: June 7, 2016
    Assignee: ETH ZURICH
    Inventors: Bastien Castagner, Jean-Christophe Leroux, Mattias Ivarsson, Gisbert Schneider, Anna Pratsinis
  • Publication number: 20150216802
    Abstract: The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the pH within the liposomes differs from the pH in the intraperitoneal cavity and wherein the pH within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes. A further aspect of the present invention relates to a method of treating patients suffering from endogenous or exogenous toxicopathies, preferably selected from drug, metabolite, pesticide, insecticide, toxin, and chemical warfare toxicopathies, more preferably hyperammonemia, comprising the step of administering liposomes of the invention in a therapeutically effective amount into the peritoneal space of a patient in need thereof. Next to human, the present invention is particularly suitable to veterinary aspects.
    Type: Application
    Filed: August 6, 2013
    Publication date: August 6, 2015
    Inventors: Jean-Christophe Leroux, Vincent Forster
  • Publication number: 20150064131
    Abstract: A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa.
    Type: Application
    Filed: September 16, 2014
    Publication date: March 5, 2015
    Applicant: Valorisation-Recherche Limited Partnership
    Inventors: Jean-Christophe Leroux, Mohamad Nasser Eddine
  • Patent number: 8883133
    Abstract: A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: November 11, 2014
    Assignee: Valorisation-Recherche Limited Partnership
    Inventors: Jean-Christophe Leroux, Mohamad Nasser Eddine
  • Publication number: 20140235590
    Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO32?, OPSO22? or OSO3?; R1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO32?, OPSO22?, ? or OSO3?; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.
    Type: Application
    Filed: September 28, 2012
    Publication date: August 21, 2014
    Applicant: ETH ZURICH
    Inventors: Bastien Castagner, Jean-Christophe Leroux, Mattias Ivarsson, Gisbert Schneider, Anna Pratsinis
  • Patent number: 8784792
    Abstract: A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: July 22, 2014
    Assignee: Valorization-Recherche Limited Partnership
    Inventors: Jean-Christophe Leroux, Mohamad Nasser Eddine
  • Publication number: 20120244105
    Abstract: A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa.
    Type: Application
    Filed: May 1, 2012
    Publication date: September 27, 2012
    Applicant: VALORISATION-RECHERCHE LIMITED PARTNERSHIP
    Inventors: Jean-Christophe Leroux, Mohamad Nasser Eddine
  • Publication number: 20110207813
    Abstract: The present invention relates to an injectable pharmaceutical composition with gelling properties containing:—an active principle; a hydrophobic and bio-compatible organic liquid; and an organogelling substance, the molecules of which have the capacity to bind together via bonds of low energy, wherein said organogelling substance is chosen among L-tyrosine derivatives responding to the following formula (I) wherein: R1 is an alkyl group containing 1 to 3 carbon atoms, linear or branched; and R2 is a hydrophobic group chosen among aliphatic saturated or unsaturated fatty chains or aryl or arylalkyl groups, Its use as a vector for the release of active principles, as well as its process of preparation.
    Type: Application
    Filed: January 30, 2009
    Publication date: August 25, 2011
    Applicants: ETHYPHARM, UNIVERSITE DE MONTREAL
    Inventors: Jean-Christophe Leroux, Guillaume Bastiat
  • Patent number: 7879966
    Abstract: A pH-sensitive polymer which has cytotoxic or membranolytic properties at pH values below pH 6.5. Carriers for natural or synthetic biomolecules or active pharmaceutical ingredients using such a pH-sensitive polymer.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: February 1, 2011
    Assignees: Evonik Roehm GmbH, Universite de Montreal
    Inventors: Hans-Ulrich Petereit, Christian Meier, Klaus Schultes, Marie-Andree Yessine, Jean-Christophe Leroux
  • Patent number: 7691408
    Abstract: The invention relates to a heat-sensitive composition in liquid form, containing: an organic hydrophobic liquid; an organogelling substance, the molecules of which can be bound to one another by low energy linkages; and a bioactive substance, which switches to organogel form upon coming into contact with a physiological fluid during the administration thereof into an animal body, in particular, a human.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: April 6, 2010
    Assignees: Ethypharm, Universite De Montreal
    Inventors: Jean-Christophe Leroux, Anne-Claude Couffin-Hoarau
  • Publication number: 20090214605
    Abstract: The present invention describes the preparation of reverse polymeric micelles (RPM) through hydrophobically-modified star-shaped polyols. More specifically, RPM are obtained from polymeric structures where the polyol constitutes the hydrophilic domain while the hydrophobic shell is obtained either through the modification of existing chemical functions (e.g. esterification) or through copolymerization with hydrocarbon (alkyl)acrylate derivatives. Hydrophilic guests can be accommodated in the micelle core opening new avenues for the use of such carriers as delivery agents for polar active compounds.
    Type: Application
    Filed: April 5, 2006
    Publication date: August 27, 2009
    Inventors: Jean-Christophe Leroux, Marie-Christine Jones, Pankaj Kumar Tewari